Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

Fineline Cube Jun 22, 2026
Company Deals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

Fineline Cube Jun 22, 2026
Company Deals

Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer

Fineline Cube Jun 22, 2026
Company Deals

Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners

Fineline Cube Jun 22, 2026
Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Fineline Cube Jun 22, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

Fineline Cube Jun 22, 2026
Company Drug

Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC

Fineline Cube Jun 22, 2026
Company Drug

Youcare’s YKYYO17 Aerosol Inhalation Agent Approved for COVID-19 Clinical Study

Fineline Cube Dec 1, 2022

China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide...

Company Deals

Henan Celnovte Biotechnology Raises RMB 100M in New Financing Round

Fineline Cube Dec 1, 2022

China-based Henan Celnovte Biotechnology Co., Ltd, a tumor in vitro diagnostic reagents (IVDs) and instruments...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 Vaccine Reduces Household Transmission of COVID-19

Fineline Cube Dec 1, 2022

China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced that Clinical Infectious Diseases has published...

Company Drug

Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study

Fineline Cube Dec 1, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...

Company Drug

Ascletis Pharma’s COVID-19 Drug Candidate ASC11 Accepted for Review by NMPA

Fineline Cube Nov 30, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its Investigational New Drug (IND) filing...

Company Deals

Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline

Fineline Cube Nov 30, 2022

China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed...

Company Deals

Fosun Pharma Weighs Sale of India’s Gland Pharma Amid Market Interest

Fineline Cube Nov 30, 2022

Shanghai Fosun Pharmaceutical Group Co. (HKG: 2196, SHA: 600196) is reportedly considering the sale of...

Company Deals

Fosun Pharma’s Gland Pharma to Acquire French CDMO Cenexi for EUR 120 Million

Fineline Cube Nov 30, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd...

Company Drug

Luye Pharma Initiates Phase II Study for LY 03014 in China

Fineline Cube Nov 30, 2022

China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...

Policy / Regulatory

China’s Drug-Eluting Stent Procurement Results Announced

Fineline Cube Nov 30, 2022

The national high-value medical consumables alliance procurement office has released the results of the successive...

Company Deals

Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement

Fineline Cube Nov 30, 2022

China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities...

Company Deals

Frontier Biotechnologies Partners with CASAPC for AIDS Prevention in China

Fineline Cube Nov 30, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced a collaboration agreement with the Chinese Association...

Company Drug

Henlius Completes First Dosing in Head-to-Head Study of PD-1 Inhibitor HanSiZhuang

Fineline Cube Nov 30, 2022

Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...

Company Deals

JancsiTech Raises Tens of Millions in Angel Round Led by Yuanbio Venture Capital

Fineline Cube Nov 30, 2022

JancsiTech, a precision nuclear medicine specialist based in Shenzhen, has reportedly raised “tens of millions”...

Company Drug

FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment

Fineline Cube Nov 30, 2022

US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA)...

Company

Sino Biological to Invest RMB 1 Billion in Beijing Bio-Pharmaceutical Park

Fineline Cube Nov 30, 2022

Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140...

Company Drug

Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment

Fineline Cube Nov 29, 2022

China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine...

R&D

Hong Kong Researchers Identify New Target for Epilepsy Treatment

Fineline Cube Nov 29, 2022

Researchers at the University of Hong Kong have published the results of a study that...

Company Drug

Hope Medicine Gains Global Approval for Phase II Trial of HMI-115

Fineline Cube Nov 29, 2022

China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...

Company Deals

Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline

Fineline Cube Nov 29, 2022

Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move...

Posts pagination

1 … 614 615 616 … 686

Recent updates

  • Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager
  • CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player
  • Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer
  • Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio
  • Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

Company Deals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

Company Deals

Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer

Company Drug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.